From the PR

Resverlogix will conclude its Phase 2 trial in hospitalized COVID-19 patients early,

·      I hope the RVX science people will have good data from the trial.

“We’re pleased to support this important evolution of apabetalone and Resverlogix in its Phase 3 CORAL study,” said Kevin McDermott, Resverlogix Chief Commercial Officer, EVERSANA. 

·      This was the first refreshing thing that struck me…an Eversana person taking on the communication function (brand champion). I hope this will be the style of the future. Unfortunately, on the Zenith side of things Don was still quoted in the PR. They should let Dr Lakhotia take on this role in the future. It would provide a much more professional image of the ZCC brand.

I am very surprised that Eversana is sticking around. They are investing their own money and they won’t get a penny for at least 3 years (my guess) if ever. Perhaps they’ve kicked the tires on the science. I assume they must have a huge payout clause in the event of an acquisition.

I’d love to see a CVR deal involving both RVX and ZCC with a large up front payment and a series of success checkpoints. This would bring in leadership, management and scientific skills that are desperately needed.

Above all this company needs leadership. Even mediocre leadership with some experience in financing would be a dramatic improvement. Some honesty would be a dream.

Anyway, no matter what happens, this is all working out perfectly for Don. He has another 3 years to collect a salary of $360,000/year and another $1,600,000/year in other benefits and by then he’ll be 66 or 67. Pretty good gig when you don’t have to achieve anything.

I remain long for obvious reasons and the science.

GLTA

Toinv